About Artera
Artera is a precision oncology company that leverages multimodal artificial intelligence to personalize cancer treatment decisions. The company's AI platform analyzes digital pathology images and clinical data to provide actionable insights for cancer management. Artera's flagship product, the ArteraAI Prostate Test, is FDA-cleared and recommended in NCCN Clinical Practice Guidelines, offering therapeutic insights for early-stage prostate cancer patients. The test predicts which NCCN Intermediate-risk patients will benefit from short-term androgen deprivation therapy with radiation, and provides risk stratification for post-prostatectomy patients. The platform has been validated in dozens of large, randomized phase III clinical trials and demonstrates consistent performance across diverse populations, including African American and non-African American men. Artera also offers the ArteraAI Breast Cancer Test, which provides 5- and 10-year distant metastasis risk estimates for early-stage breast cancer patients and predicts chemotherapy benefit for node-negative patients 50 years or older. The company's tests utilize existing H&E slides without requiring additional tissue consumption or special staining, delivering results within 1-2 days through their CLIA-certified laboratory. Artera's mission is to establish a more personalized approach to cancer treatment by combining cutting-edge AI technology with clinical expertise.
Mission & Story
Mission
Cancer is personal. Cancer therapy should be, too.
Founding Story
Founded by CEO Andre Esteva PhD and Co-Founder Felix Feng MD (In Memoriam), the company was built on a shared goal of establishing a more personalized approach to cancer treatment, combining expertise in AI and medical oncology.
Clinical Focus
Medical conditions and clinical areas addressed by Artera.
Who It Serves
Milestones & Awards
Recent Milestones
FDA De Novo Authorization for ArteraAI Prostate Test, expansion to metastatic hormone-sensitive prostate cancer (mHSPC) announced June 4, 2026, first digital pathology-based test for mHSPC, inclusion in NCCN Clinical Practice Guidelines
Awards & Recognition
FDA Breakthrough Device Designation, first and only AI test recommended in NCCN Clinical Practice Guidelines for Prostate Cancer, first-of-its-kind AI-powered digital pathology risk stratification tool
Social & Media
Latest Updates
Artificial Intelligence in Oncology: Clinical Applications, Challenges, and Opportunities
Tempus and Artera Collaborate to Expand Access to New Prognostic Test for Prostate Cancer
External Validation of a Post-RP Multimodal AI Prognostic Model
ASCO 2026: The biggest trends for marketers to watch
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer
Company Details
- Headquarters
- San Francisco, CA, USA
- Employees
- 11-50
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 31 →
Belong.life
series b · 75 employees
Belong.Life provides AI health mentors, patient communities, and education for people with chronic diseases including a social network and navigator app for cancer patients.
Buoy Health
Buoy Health is an AI-powered digital health platform that helps consumers navigate healthcare by checking symptoms, providing clinical insights, and connecting them to appropriate care options through a personalized marketplace of health services.
CareMessage
CareMessage is a technology nonprofit building the largest patient engagement platform for low-income populations in the United States. The platform delivers automated, AI-powered messaging and health coaching to improve access to care, clinical outcomes, and address social determinants of health for safety-net healthcare organizations.
CipherHealth
CipherHealth provides AI-powered care coordination software for health systems, connecting nurse rounding, patient outreach, and post-discharge follow-up in one platform. The company helps hospitals reduce readmissions, improve patient experience, and save nursing time through automated workflows and conversational AI.
Conversa Health
Conversa Health provides AI-powered conversational care solutions that enable healthcare organizations to automate patient engagement, monitoring, and support through personalized digital conversations.
DexCare
DexCare provides patient navigation infrastructure that routes patients to appropriate care across fragmented health systems. The platform connects data from multiple sources to help patients find available appointments while optimizing provider schedules and capacity utilization.
Get Well
Get Well provides a comprehensive digital patient engagement platform that spans the entire care continuum—inpatient, outpatient, community, and home. The company delivers award-winning interactive patient care solutions with AI-powered tools and live navigators to drive clinical, financial, and operational outcomes for health systems, hospitals, health plans, and government healthcare organizations.
Gozio Health
Gozio Health provides a Mobile Experience Platform that unifies patient-facing digital tools into a single branded app for health systems. The platform integrates wayfinding, scheduling, patient portals, and 30+ healthcare solutions to create seamless patient journeys from home to point of care.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.